1. Home
  2. DSP vs NKTX Comparison

DSP vs NKTX Comparison

Compare DSP & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$10.60

Market Cap

213.3M

Sector

Technology

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.63

Market Cap

247.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSP
NKTX
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
213.3M
247.4M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DSP
NKTX
Price
$10.60
$2.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
$17.81
$11.33
AVG Volume (30 Days)
179.7K
948.3K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
157.14
11.88
EPS
0.36
N/A
Revenue
$344,201,000.00
N/A
Revenue This Year
$20.27
N/A
Revenue Next Year
$16.88
N/A
P/E Ratio
$29.56
N/A
Revenue Growth
19.00
N/A
52 Week Low
$8.11
$1.63
52 Week High
$16.25
$3.65

Technical Indicators

Market Signals
Indicator
DSP
NKTX
Relative Strength Index (RSI) 48.22 49.46
Support Level $8.49 $1.88
Resistance Level $10.73 $2.66
Average True Range (ATR) 0.69 0.27
MACD -0.04 -0.02
Stochastic Oscillator 39.36 32.57

Price Performance

Historical Comparison
DSP
NKTX

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: